UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: July 23, 2014
(Date of earliest event reported)
BIO-RAD LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 1-7928
| Delaware | 94-1381833 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
1000 Alfred Nobel Dr.
Hercules, California 94547
(Address of principal executive offices, including zip code)
(510) 724-7000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation
of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pare-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 23, 2014, Bio-Rad Laboratories, Inc. (the “Company”) appointed Joel McComb to its Board of Directors. Mr. McComb will stand for election to the Board along with the Company’s other directors at the Company’s annual meeting of stockholders next year. There is no arrangement or understanding pursuant to which Mr. McComb was appointed as director.
On the same basis as the other non-employee directors of the Company, Mr. McComb will be entitled to receive a fee of $7,083 per month and reimbursement of travel expenses to Board meetings.
Item 9.01 Financial Statements and Exhibits
Exhibit Number | Description | |
| 99.1 | Press release of Bio-Rad Laboratories, Inc. dated July 25, 2014 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BIO-RAD LABORATORIES, INC. | ||||
| Date: | July 25, 2014 | By: | /s/ Christine A. Tsingos | |
| Christine A. Tsingos | ||||
| Executive Vice President and Chief Financial Officer | ||||
EXHIBIT INDEX
Exhibit Number | Description | |
| 99.1 | Press release of Bio-Rad Laboratories, Inc. dated July 25, 2014 | |